Sustainability at Roche UK
Through our transformative medicines and diagnostic solutions we contribute to improving outcomes for patients. Doing it sustainably reflects our unwavering commitment to all our stakeholders and future generations.
Our Sustainability Strategy builds on our purpose and establishes clear priorities to create long-term societal and financial value. We are taking action to integrate sustainability into everything we do and focus on three areas where we can have the most impact:
Access to innovation
We want to maximise access to our innovative medicines and diagnostics solutions and advance equitable health outcomes for all patients worldwide.
People
We are committed to fostering a work environment where people are treated fairly, respectfully and can thrive.
Environment
We aim to make a positive contribution to the health of nature, water systems, climate and people. Roche is determined to achieve net-zero greenhouse gas emissions in its own operations and value chain (Scopes 1, 2, and 3) by 2045. To stay on track, we've set clear near-term and long-term SBTi validated targets.
Read about our progress towards our commitment to achieving Net Zero:
Social value at Roche UK
At Roche, we believe that being a healthcare leader comes with a broader responsibility to the society we serve. We are more than a healthcare company; we are a long-term partner to the UK’s health, economy, and environment. From our net-zero ambitions and STEM outreach to our localised health equity projects, we are committed to generating measurable social, environmental, and economic value. At Roche, we innovate today to ensure a healthier, fairer tomorrow for communities across the UK. Read about our progress in our latest social value report.
Our reporting
Roche is committed to transparent reporting, and we endeavour to drive our economic, social and environmental performance with the same diligence as our financial performance. You can learn more here.
Tackling global health inequalities
Universal access to quality healthcare and medical innovation remains a global challenge. To address this challenge, many of the world’s top relief and aid organisations have joined together with an ambitious goal: to eliminate many diseases. In support of this ambition, Roche Diagnostics launched a Global Access Program which provides access to diagnostics for HIV, hepatitis, tuberculosis and cervical cancer (HPV), in high disease burden and qualified countries where reliable diagnostic solutions are needed most.
M-GB-00026181 Date of Preparation April 2026